Novel breath test shows promise in distinguishing fibrotic lung diseases

Recent research presented at the American College of Chest Physicians Annual Meeting in Arizona highlights targeted sphingolipid profiling via high-performance liquid chromatography–tandem mass spectrometry as a promising method to characterize and assess fibrotic interstitial lung disease. The study suggests that exhaled sphingolipids may help differentiate idiopathic pulmonary fibrosis from other fibrotic lung conditions, warranting further investigation.

Originally published by gnews